Experimental Data Snapshot
(2014) Drug Discov Today 19: 905-911
Cytochrome P450 (CYP) enzymes are key players in xenobiotic metabolism, and inhibition of CYPs can therefore result in unwanted drug-drug interactions. Within drug discovery, CYP inhibition can cause delays in the progression of candidate drugs, or even premature closure of projects. During the past decade, a massive effort in the pharmaceutical industry and academic research has produced a wealth of structural information in the CYP field. In this short review, we will describe how structure-based approaches can be used in the pharmaceutical industry to work away from CYP inhibition, with a focus on the opportunities and challenges. We will show two examples from our own work where structural information on CYP2C9 and CYP3A4 inhibitor complexes have been successfully exploited in ongoing drug discovery projects.
Department of Chemistry and Molecular Biology, University of Gothenburg, Göteborg S-405 30, Sweden. Electronic address: gisela.branden@gu.se.
 Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report |Ligand Interaction (HEM)
Biological assembly 1 assigned by authors.
 Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report |Ligand Interaction (HEM)
Biological assembly 2 generated by PISA (software)
Macromolecule Content
Entity ID: 1 | |||||
---|---|---|---|---|---|
Molecule | Chains | Sequence Length | Organism | Details | Image |
Cytochrome P450 3A4 | 484 | Homo sapiens | Mutation(s): 0  Gene Names: CYP3A3, CYP3A4, CYP3A4 CYP3A3 EC: 1.14.13 (PDB Primary Data), 1.14.13.157 (PDB Primary Data), 1.14.13.32 (PDB Primary Data), 1.14.13.67 (PDB Primary Data), 1.14.13.97 (PDB Primary Data), 1.14.14.73 (UniProt), 1.14.14.1 (UniProt), 1.14.14.56 (UniProt), 1.14.14.55 (UniProt) | ![]() | |
UniProt & NIH Common Fund Data Resources | |||||
Find proteins for P08684 (Homo sapiens) Explore P08684  Go to UniProtKB:  P08684 | |||||
PHAROS:  P08684 GTEx:  ENSG00000160868  | |||||
Entity Groups  | |||||
Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
UniProt Group | P08684 | ||||
Sequence AnnotationsExpand | |||||
|
Ligands 2 Unique | |||||
---|---|---|---|---|---|
ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
HEM Query on HEM Download Ideal Coordinates CCD File  | B [auth A] | PROTOPORPHYRIN IX CONTAINING FE C34 H32 Fe N4 O4 KABFMIBPWCXCRK-RGGAHWMASA-L | |||
2QH Query on 2QH Download Ideal Coordinates CCD File  | C [auth A] | (8R)-3,3-difluoro-8-[4-fluoro-3-(pyridin-3-yl)phenyl]-8-(4-methoxy-3-methylphenyl)-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine C25 H22 F3 N5 O YGQLOGGNUHAJMB-RUZDIDTESA-N |
Length ( Å ) | Angle ( ˚ ) |
---|---|
a = 78.548 | α = 90 |
b = 101.692 | β = 90 |
c = 132.422 | γ = 90 |
Software Name | Purpose |
---|---|
MOSFLM | data reduction |
SCALA | data scaling |
PHASER | phasing |
BUSTER-TNT | refinement |
PDB_EXTRACT | data extraction |
BUSTER | refinement |
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729.